Publications by authors named "A Segot"
Acute leukemias are rare diseases requiring emergency specialized hematological care. However, other specialists may be involved: general practitioners, emergency physicians, internists and intensivists most often. The initial phase of the management of acute leukemia can be marked by the occurrence of complications with a significant impact on morbidity and mortality.
View Article and Find Full Text PDFArticle Synopsis
- The study identifies biomarkers that can differentiate between immune-related cytokine release syndrome (irCRS) and sepsis in oncology patients undergoing immune checkpoint inhibitor therapy.
- The analysis revealed that hepatocyte growth factor (HGF) and ferritin are particularly effective in predicting outcomes related to irHLH and Grade 3 irCRS, with a 100% positive and negative predictive value.
- Patients with severe irCRS who did not respond to corticosteroids showed complete resolution after treatment with tocilizumab (TCZ), highlighting the potential for targeted therapies in these cases.
Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines.
Eur J Cancer
December 2024
Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management.
View Article and Find Full Text PDFArticle Synopsis
- Diagnosis of primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is often difficult and delayed due to low sensitivity of standard tests like MRI, CSF cytology, and even brain biopsies.
- In three reported cases, novel CSF biomarkers, including the MYD88 L265P mutation and specific cytokine levels, helped suggest the diagnosis of PCNSL, which was later confirmed by biopsy or autopsy.
- The study highlights five key CSF biomarkers (IL-10, IL-10/IL-6 ratio, CXCL13, MYD88 mutation, and monoclonal immunoglobulin rearrangements) that can improve diagnostic accuracy for PCNSL.